D. Bae

Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis

E. Lee, E. Lee, Yeong-Wook Song, 2020, Arthritis Research & Therapy.

CKD-506: A novel HDAC6-selective inhibitor that exerts therapeutic effects in a rodent model of multiple sclerosis

Hee Seon Lim, Jinsol Park, Ji-Young Lee, 2021, Scientific Reports.

A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot–Marie–Tooth disease type 1A

Soyeon Jeong, G. Kwak, Byung-Ok Choi, 2020, British journal of pharmacology.

M-134, a novel HDAC6-selective inhibitor, markedly improved arthritic severity in a rodent model of rheumatoid arthritis when combined with tofacitinib

Jinsol Park, Jiyoung Lee, W. Son, 2020, Pharmacological Reports.

Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro

E. Lee, E. Lee, J. Park, 2017, Arthritis Research & Therapy.

Inhibition of histone deacetylase 6 suppresses inflammatory responses and invasiveness of fibroblast-like-synoviocytes in inflammatory arthritis

J. Park, T. Pap, H. Yoo, 2021, Arthritis Research & Therapy.

Development of a tetrahydroindazolone-based HDAC6 inhibitor with in-vivo anti-arthritic activity.

Gibeom Nam, D. Bae, Changsik Lee, 2024, Bioorganic & medicinal chemistry.